Table 2.
Results summary
| Effect on sensitivity to contingency degradation | Degradation | Baseline | ||
|---|---|---|---|---|
| Inactivation | Overactivation | Inactivation | Overactivation | |
| Area 24 (perigenual ACC) | Blunted | Blunted | No effect | Decreased across juice conditions |
| Area 11 (antOFC) | Enhanced | Blunted | No effect | No effect |
| Area 14-25 (caudal vmPFC) | No effect | No effect | No effect | No effect |
| Area 32 (mPFC) | No effect | No effect | Juice 2 > juice 1 | Juice 2 > juice 1 |
| Area 14 (rostral vmPFC/ mOFC) | No effect | Blunteda | No effect | Decreased in juice 2 |
| Caudate nucleus (anteromedial) | Blunted | N/A | No effect | N/A |
a
This blunting of the sensitivity to contingency degradation may be due to a non-specific drug effect observed in the baseline sessions (see Results).